Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. - Wikidata - wikimedia - TriplyDB

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

http://www.wikidata.org/entity/Q41870799

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment Combining radiotherapy and cancer immunotherapy: a paradigm shift The roles of Galectin-3 in autoimmunity and tumor progression Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice Strategies to overcome obstacles to successful immunotherapy of melanoma Use of tumour-responsive T cells as cancer treatment.Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice.Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.Defining the critical hurdles in cancer immunotherapy.Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates.Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection.In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.Combining radiotherapy and immunotherapy: a revived partnership.High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.Checkpoint blockade in cancer immunotherapy Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy.Vaccination: role in metastatic melanoma.NY-ESO-1 immunotherapy for multiple myeloma.Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity Immune correlates of melanoma survival in adoptive cell therapy.Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway Tumor-associated antigens and biomarkers in cancer and immune therapy.Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.

P2860

Q21131200-DC9ACC06-EFD8-4B31-B39B-E14986F72A9A Q26799117-B0B51E53-F8AF-497B-834D-C4BC4943C733 Q27021428-2863482C-1579-4D07-ADC9-2184EF5E6A06 Q28261890-CA84F627-6CF2-4B22-A1F9-9C4C4990C700 Q30481516-84C9CB63-7979-4F7F-8D32-979309E1B331 Q30525394-B15F8645-A929-4B34-B38D-256B8666EF85 Q30846001-8B960D1B-858C-4378-8875-25334EB7FCA4 Q33530527-5E57EE55-E6A9-4C37-BD5E-F8B4E0273414 Q33613602-AA06EA54-945E-4B91-95F3-AE52717CCED3 Q33765767-F898D7B2-4648-4E6B-9247-C9D00D898A87 Q33776452-F156CF3B-1A11-4CCF-A573-A60D06846500 Q34042968-43564171-6788-4519-AEA7-EB79832A885C Q34285656-EC86D4C7-A85E-450E-BDCE-B794ACE890EE Q34448082-016B5147-B077-43B0-B191-09A91E0A49A8 Q34627677-8E21A077-E094-42C7-9515-CD51BF24B30C Q34691545-CBFCC804-6AD9-4FE3-BA72-AA3524669808 Q34736597-8B035664-7C41-44FA-A7CB-46CE8D997D18 Q35012393-B7A6815B-964E-4765-8C13-A8D3A9AD5BEE Q35201915-90B6F13A-99A2-46CC-B1F3-346A2D899715 Q35751259-8188760C-1336-475D-A80A-C985151B6E50 Q35889604-28B1E445-BE9C-42BC-9313-4271D1DFEB14 Q35916968-1EF793A4-0192-457B-9B74-97573AFCD52C Q35939427-E415EFDB-43D6-43E4-A521-075C6FAB3FE7 Q36071705-AB586097-E4E8-4430-A49E-0E945BCF4DEB Q36185636-F0EDEC9F-A838-4638-8D26-F0DEEA3691CF Q36228011-894B8DF9-296F-46FA-9E18-C338EADCB762 Q36229738-DE019A06-FBE3-4A02-8529-BBA8306B521E Q36274581-0A56BB80-E19E-481E-B2A4-250D44CCF55D Q36402611-1455305B-1482-4476-9F37-1DD3C520967B Q36490768-0D2A1746-DAFE-4A4B-B818-9B6ED941E1F7 Q36568984-A7AC6094-32E1-49E7-A1F0-578E8A3C783B Q36573868-E030357C-714F-4A16-9C29-60A174A040E9 Q36637651-D4905DBC-CECA-4E3A-9471-C51A268AB637 Q36664213-A90715E8-04F6-437B-B4C1-B8D3C49D9F70 Q36693023-1F2E0F8B-8441-4E41-9F67-6F154108CD16 Q36694896-4B74F03E-A01E-4833-9F18-F8D0A094B5B6 Q36742295-F57A8087-A38C-4C3E-9152-07433C0A10C5 Q36786880-677A2439-1833-449E-AB5A-2441FB4AEF45 Q36844959-B6A1CB40-6955-410D-9358-CF00683D651A Q36859171-FEFF26EB-54DC-404E-A9EC-B58D2679C296

P2860

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

http://www.wikidata.org/entity/Q41870799

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Contrasting frequencies of ant ...... ted with a MAGE tumor antigen.

@en

type

label

Contrasting frequencies of ant ...... ted with a MAGE tumor antigen.

@en

prefLabel

Contrasting frequencies of ant ...... ted with a MAGE tumor antigen.

@en

P1433

Q41870799-50882890-73FA-4B42-815D-C23296B6A190

P1476

Q41870799-F79D12D0-64CA-463B-B187-CAE26D8A5A22

P2093

Q41870799-002D43BF-2F54-4B5C-9868-2C34557B55B6

Q41870799-29E41CFA-324F-4CCC-9242-879B59E1F48C

Q41870799-35CC12A8-28AE-4480-AB9A-085CE32A1134

Q41870799-6156D324-50B4-407A-BF13-314C82C7FEB9

Q41870799-A2C45449-D060-4A45-BE0A-B270DDF43C90

Q41870799-AB7FC1DA-5400-4689-82C9-04F358DCF1BB

Q41870799-B577932F-A158-4794-985B-C712892FF8F6

Q41870799-F28F2745-CA47-4A17-A602-DB8B84E4BCCB

P2860

Q41870799-0050507F-0FB4-4BF7-8C4C-5B1E0CB0E996

Q41870799-07780524-63E8-4A8B-AFDF-127DFBEF6241

Q41870799-0AC0DC3E-CEC4-4279-930C-37FB4A6DB849

Q41870799-1B0D34F4-ABD3-4C5D-B806-BD169FF628C1

Q41870799-269191A2-07D1-4137-AF9E-551BD0401877

Q41870799-3AC9C165-1A8D-433A-BDF9-65B8E0F441C0

Q41870799-3C79EBD7-B18A-4FC1-90D4-3B1EC855F696

Q41870799-49112C83-7BC5-40D2-A27A-F4530CACE4BE

Q41870799-5CB204A6-DF7A-47C2-8CCF-FE2E2D1D77EE

Q41870799-6152C536-E7B8-4A34-B3AC-0AB03B061099

P304

Q41870799-91DB6386-57C7-43A4-83D3-CA6B895A9FF5

P31

Q41870799-131C8C78-BE05-4C1A-9F2F-F4AF6B0DD5C5

P356

Q41870799-1E02E739-63D0-477B-A02E-B9AB61E914AB

P407

Q41870799-C4769918-012F-4241-8ADA-BE82A7784F4A

P433

Q41870799-6085678F-5974-49CC-A1CF-B51CA98A82C0

P478

Q41870799-19C6E3C4-C510-4945-BDC3-35D13BDD03EA

P577

Q41870799-EB7D51F9-50FC-4583-8465-0E6E64C25690

P5875

Q41870799-8822D4CD-E998-44C0-A54D-9E047524EC56

P698

Q41870799-3561439E-0FA5-42CE-A79D-44988E1859E2

P921

Q41870799-CC77AF86-9868-4F3B-B003-8B49C56B094F

P932

Q41870799-A638C637-CB31-4E54-8752-ECF0405B9666

P356

P1433

Journal of Experimental Medicine

P1476

Contrasting frequencies of ant ...... ted with a MAGE tumor antigen.

@en

P2093

Bernard Lethé

http://www.w3.org/2001/XMLSchema#string

Christophe Lurquin

http://www.w3.org/2001/XMLSchema#string

Etienne De Plaen

http://www.w3.org/2001/XMLSchema#string

Ivan Théate

http://www.w3.org/2001/XMLSchema#string

Nicolas van Baren

http://www.w3.org/2001/XMLSchema#string

Pierre G Coulie

http://www.w3.org/2001/XMLSchema#string

Thierry Boon

http://www.w3.org/2001/XMLSchema#string

Véronique Corbière

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Mutations of the BRAF gene in human cancer

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

P304

249-257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20041378

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8074718

http://www.w3.org/2001/XMLSchema#string

P698

15657294

http://www.w3.org/2001/XMLSchema#string

P921

P932

2212799

http://www.w3.org/2001/XMLSchema#string